Bariatric Surgery
Conditions
Brief summary
With 6.5 million obese recorded in France in 2009, obesity is a major public health: it is a chronic disease associated with many respiratory, cardiac, metabolic, musculoskeletal complications. The risk of mortality and morbidity are directly proportional to the importance of overweight and medical treatment alone is only moderately effective weight loss. Bariatric surgery is the only treatment with proven efficacy in patients with a body mass index above 40 kg/m2. As with any surgery, there is a risk of surgical site infection (SSI). The SSI are the third most common nosocomial infection after urinary tract infections and airway. The fight against the ISO requires the administration of antibiotic prophylaxis acting on the main bacteria found in bariatric surgery. There are several studies in the literature interested in the dose of cefazolin in bariatric surgery. However, no published pharmacokinetic studies defines an optimal dose to obtain tissue and plasmatic concentrations of cefazolin higher than minimum inhibitory concentrations of the main germs encountered in these surgery. Only empirical recommendations are published, including the SFAR and the National Institute of Health in 2010. This study aims to determine whether the dose of 4 grams of cefazolin can achieve these goals of concentration and estimate an injection time of preoperative ideal for an adequate tissue concentration at the time of the incision.
Interventions
DRUGCefazoline
Injection of CEFAZOLINE (4 grams) 30-60 min before skin incision. A second injection will performed every 4 hours during the surgery
Sponsors
Nantes University Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Male or female, aged \> 18 years. * BMI ≥ 40 and ≤ 65 kg/m2. * The patient has given informed consent in writing.
Exclusion criteria
* Age less than 18 years and above 70 years. * Major Trust. * Pregnancy. * Moderate to severe renal insufficiency or clearance creatinine clearance \<60 ml / min * Hypersensitivity to cephalosporins and beta-lactams.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tissue concentration of cefazolin in the superficial subcutaneous fat during the surgical procedure | At the time of incision (T0), 1 hour of operation (T1), and at the closure (T2) |
Secondary
| Measure | Time frame |
|---|---|
| Kinetics of tissue concentrations of the superficial subcutaneous fat during surgery in patients with BMI < 50 and patients with BMI > 50 | At the time of incision (T0), 1 hour of operation (T1), and at the closure (T2) |
| Kinetics of tissue concentrations of the deep fat peri gastric during surgery in patients with BMI < 50 and patients with BMI > 50 | At the time of incision (T0), 1 hour of operation (T1), and at the closure (T2) |
| Cefazolin tissue concentrations in fatty deep peri gastric tissue throughout the intervention | At the time of incision (T0), 1 hour of operation (T1), and at the closure (T2) |
| Number of SSI following the surgery. | Within 30 days post-surgery |
| Area Under Curve (AUC) of cefazolin plasma kinetics for each group | Surgical incision,15,30,60 minutes post-incision, surgical closure |
| Kinetics of plasma concentrations during surgery in each group | At the time of incision, at 15, 30, 60 minutes of operation, and at the closure |
Countries
France
Outcome results
None listed